CRP and type 2 diabetes mellitus: In conclusion, after 18 months’ treatment, rosiglitazone in combination with metformin or sulphonylurea, is as effective in lowering HbA1c in people with Type 2 diabetes as the standard combination of metformin + sulphonylurea, and produces greater improvements in CRP and insulin sensitivity but is also associated with greater weight gain.